In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

Identifying the mechanisms of action driving a drug’s anti-cancer efficacy is critical for identifying optimal biomarkers, indications, and combinations for clinical success. Yet, systematically ...